Synergism and rules from combination of Baicalin, Jasminoidin and Desoxycholic acid in refined Qing Kai Ling for treat ischemic stroke mice model.
Refined Qing-Kai-Ling (QKL), a modified Chinese medicine, consists of three main ingredients (Baicalin, Jasminoidin and Desoxycholic acid), plays a synergistic effect on the treatment of the acute stage of ischemic stroke. However, the rules of the combination and synergism are still unknown. Based on the ischemic stroke mice model, all different kinds of combination of Baicalin, Jasminoidin, and Desoxycholic acid were investigated by the methods of neurological examination, microarray, and genomics analysis. As a result, it confirmed that the combination of three drugs offered a better therapeutical effect on ischemic stroke than monotherapy of each drug. Additionally, we used Ingenuity pathway Analysis (IPA) and principal component analysis (PCA) to extract the dominant information of expression changes in 373 ischemia-related genes. The results suggested that 5 principal components (PC1-5) could account for more than 95% energy in the gene data. Moreover, 3 clusters (PC1, PC2+PC5, and PC3+PC4) were addressed with cluster analysis. Furthermore, we matched PCs on the drug-target networks, the findings demonstrated that Baicalin related with PC1 that played the leading role in the combination; Jasminoidin related with PC2+PC5 that played a compensatory role; while Desoxycholic acid had the least performance alone which could relate with PC3+PC4 that played a compatible role. These manifestations were accorded with the principle of herbal formulae of Traditional Chinese Medicine (TCM), emperor-minister-adjuvant-courier. In conclusion, we firstly provided scientific evidence to the classic theory of TCM formulae, an initiating holistic viewpoint of combination therapy of TCM. This study also illustrated that PCA might be an applicable method to analyze the complicated data of drug combination.
School of Basic Medical Science, Beijing University of Chinese Medicine, Beijing, People's Republic of China.
Jian
J
Li
Run-guo
RG
Wu
Fan-yun
FY
Meng
Zhong
Z
Wang
Chang-ming
CM
Wang
Yong-yan
YY
Wang
Zhan-jun
ZJ
Zhang
D000818:Animals; D016000:Cluster Analysis; D019295:Computational Biology / Q000379:methods; D003840:Deoxycholic Acid / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005419:Flavonoids / Q000008:administration & dosage*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D039823:Iridoids / Q000008:administration & dosage*; D007511:Ischemia / Q000188:drug therapy*; D008297:Male; D051379:Mice; D015233:Models, Statistical; D020411:Oligonucleotide Array Sequence Analysis; D016133:Polymerase Chain Reaction / Q000379:methods; D025341:Principal Component Analysis; D020521:Stroke / Q000188:drug therapy*
D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D004791:Enzyme Inhibitors; D005419:Flavonoids; D039823:Iridoids; C504928:Qingkailing; D003840:Deoxycholic Acid; C007835:geniposide; C038044:baicalin